These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8140212)

  • 21. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin and the prevention of thrombosis.
    J R Soc Health; 1993 Jun; 113(3):114. PubMed ID: 8320685
    [No Abstract]   [Full Text] [Related]  

  • 23. Harnessing the platelet.
    Futterman LG; Lemberg L
    Am J Crit Care; 1997 Sep; 6(5):406-14. PubMed ID: 9283679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
    Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.
    Lee PY; Chen WH; Ng W; Cheng X; Kwok JY; Tse HF; Lau CP
    Am J Med; 2005 Jul; 118(7):723-7. PubMed ID: 15989905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients].
    Addad F; Hassine M; Ben Farhat M; Abderrazak F; Chakroun T; Gamra H; Hamdi S; Betbout F; Samama M; Elalamy I
    Arch Mal Coeur Vaiss; 2005 Oct; 98(10):979-83. PubMed ID: 16294543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Am J Cardiol; 2005 Oct; 96(8):1095-9. PubMed ID: 16214444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Primary prevention of coronary heart disease with aspirin].
    Kübler W
    Z Kardiol; 2004; 93 Suppl 2():II33-6. PubMed ID: 15021994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
    Zuern CS; Lindemann S; Gawaz M
    Semin Thromb Hemost; 2009 Apr; 35(3):295-306. PubMed ID: 19452405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Problem with aspirin as antithrombotic agent in coronary artery disease.
    Folts JD; Rowe GG; Rao GH
    Lancet; 1988 Apr; 1(8591):937-8. PubMed ID: 2895855
    [No Abstract]   [Full Text] [Related]  

  • 37. [Acetylsalicylic acid. The dosage question].
    Stormorken H
    Tidsskr Nor Laegeforen; 1987 Jan; 107(2):183-4. PubMed ID: 3824309
    [No Abstract]   [Full Text] [Related]  

  • 38. Aspirin and coronary artery disease.
    Mehrotra TN; Katira R
    J Indian Med Assoc; 1991 Aug; 89(8):215-6. PubMed ID: 1748796
    [No Abstract]   [Full Text] [Related]  

  • 39. Prophylactic aspirin?
    Frank MJ; Frank N
    Ann Intern Med; 1973 Mar; 78(3):462. PubMed ID: 4694912
    [No Abstract]   [Full Text] [Related]  

  • 40. Serotonin and coronary artery disease.
    N Engl J Med; 1991 Sep; 325(12):889-91. PubMed ID: 1875978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.